Open AccessPending questions in venous ulcers management. Report from a Symposium of the World Union of Wound Healing Societies International Congress
Author(s) -
Giorgio Guarnera,
Paolo Zamboni,
Olle Nelzén,
Ferdinando Mannello,
Anneke Andriessen
Publication year - 2020
Publication title -
veins and lymphatics
Language(s) - English
Resource type - Journals
ISSN - 2279-7483
DOI - 10.4081/vl.2020.9206
Subject(s) - medicine , context (archaeology) , adverse effect , intensive care medicine , wound healing , surgery , bioinformatics , paleontology , biology
Venous ulcers represent the most frequent ulcers and have a high clinical and socioeconomic significance. Nevertheless, pending questions remain on epidemiology, genetic and biomolecular mechanisms, contraindications and risk factors of compression therapy, role of pharmacological therapy. Overall prevalence in the range of 1-2% and point prevalence of 0.08-0.6% can be reduced if risk factors are identified and treated early. In this context, analysis of factor XIII and hemocromatosis gene polymorphisms, with the C282Y and H63D variants, may be of great importance. Also MMP12 gene polymorphism and the imbalance between matrix metalloproteinases and their tissue inhibitors are able to impair wound healing via deleterious degradation process of extra-cellular matrix. From a therapeutic point of view, conflicting recommendations exist on relative contraindications, risks and adverse events of compression therapy. Some studies showed that the administration of pentoxyphilline, Micronized purified flavonoid fraction (MPFF) and sulodexide was effective in accelerating ulcer healing, but there is no data on the duration of treatment, recurrence rates and cost-effectiveness relationship.